Short Interest in Bionano Genomics, Inc. (NASDAQ:BNGO) Grows By 11.4%

Bionano Genomics, Inc. (NASDAQ:BNGO) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 17,650,000 shares, an increase of 11.4% from the December 31st total of 15,840,000 shares. Approximately 12.7% of the shares of the stock are sold short. Based on an average daily volume of 6,670,000 shares, the days-to-cover ratio is currently 2.6 days.

Analysts Set New Price Targets

Separately, LADENBURG THALM/SH SH downgraded shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a research note on Friday, November 15th.

Bionano Genomics Trading Up 2.1 %

Shares of Bionano Genomics stock traded up $0.11 on Monday, hitting $5.30. The stock had a trading volume of 233,420 shares, compared to its average volume of 352,757. The stock has a 50 day moving average of $12.61 and a 200 day moving average of $20.61. The firm has a market capitalization of $10.35 million, a P/E ratio of -0.04 and a beta of 2.22. Bionano Genomics has a twelve month low of $4.75 and a twelve month high of $81.00. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.99 and a current ratio of 1.43.

Hedge Funds Weigh In On Bionano Genomics

Several large investors have recently modified their holdings of BNGO. Carret Asset Management LLC raised its holdings in Bionano Genomics by 89.0% during the 3rd quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after purchasing an additional 40,055 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of Bionano Genomics during the third quarter valued at approximately $46,000. Finally, Geode Capital Management LLC lifted its stake in shares of Bionano Genomics by 47.3% in the third quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock valued at $401,000 after buying an additional 283,639 shares in the last quarter. Institutional investors own 11.35% of the company’s stock.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.